PNPLA3 and metabolic dysfunction-associated steatotic liver disease: At generalized linear model adjusted for sex, age, steatosis ≥ 2 and alimentary niacin, the presence of the PNPLA3 CG/GG mutation was independently associated with serum niacin in NAFLD individuals with BMI ≥ 30 kg/m2 (β = –0.21, 95% CI: –0.41–0.004, p = 0.04, Table 1), thereby supporting that PNPLA3 p.I148M aminoacidic substitution may be directly involved in the alteration of systemic niacin availability and that the effect attributable to this mutation may be amplified by adiposity.